MedTrace Logo

Short-term Glucocorticoid Combined with MMF for IgG4-RD

NCT06663618 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-10-29

No results posted yet for this study

Summary

Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease

Conditions

Interventions

DRUG

prednison

Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.

DRUG

Mycophenolate mofetil

Oral Mycophenolate mofetil 0.75g bid for 6 months.

Sponsors & Collaborators

  • Wen Zhang

    lead OTHER

Principal Investigators

  • Wen Zhang, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-03-01
Completion
2025-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663618 on ClinicalTrials.gov